Company news

Longeveron Inc. news in 2022

Longeveron Inc.'s news releases, calls and decks from 2022, newest first.

View company

Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 13, 2022

Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’s Disease

November 9, 2022

Longeveron to Announce Third Quarter 2022 Financial Results on November 14, 2022

November 6, 2022

Longeveron Names Jerome Bailey Vice President of Business Operations

September 14, 2022

Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy Through Levels of Vascular Biomarker

August 24, 2022

Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results

August 11, 2022

Longeveron to Announce Second Quarter 2022 Financial Results on August 12, 2022

August 7, 2022

Longeveron Announces Abstract Accepted for Presentation at the Alzheimer’s Association International Conference (AAIC)

July 6, 2022

Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results

May 12, 2022

Longeveron to Announce First Quarter 2022 Financial Results on May 13, 2022

May 8, 2022

Longeveron Announces CEO Transition

May 8, 2022

Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer’s Trial

April 12, 2022

Longeveron Expands Executive Leadership Team; Appoints K. Chris Min, M.D., Ph.D. as Chief Medical Officer

April 4, 2022

Longeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress

March 10, 2022

Longeveron to Announce Fourth Quarter and Full Year 2021 Financial Results, on March 11, 2022

March 6, 2022

Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors

February 16, 2022

Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging

January 11, 2022

Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease

January 4, 2022

Calls in 2022

Decks in 2022